[ad_1]
Presentation
on Tuesday December 15th at
10:40am EST
LOS ANGELES, CA – 
Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a
biopharmaceutical company focused on the development and commercialization of
treatments for rare and orphan dermatologic diseases, today announced that it
will be presenting at the 13th annual LD Micro Main Event investor conference
on Tuesday, December 15, 2020 at 10:40 AM EST / 7:40 AM PST. John Koconis,
Chief Executive Officer of Timber Pharma, will be presenting to a live, virtual
audience.
Register
here: ve.mysequire.com/
The Main
Event will feature a new and unique format, with companies presenting for 10
minutes, followed by 10 minutes of Q&A by a panel of investors and
analysts.
“The
time has finally come to do something different in the virtual conference
world. Let’s see if we can pull off something that can be enjoyed by both
executives and investors alike,” stated Chris Lahiji, Founder of LD, now a
wholly owned subsidiary of SRAX, Inc.
The Main
Event will take place on December 14th and 15th, exclusively on the Sequire
Virtual Events platform.
View Timber
Pharmaceuticals profile here: http://www.ldmicro.com/profile/TMBR
Profiles
powered by LD
Micro
About
Timber Pharmaceuticals, Inc.
Timber
Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development
and commercialization of treatments for rare and orphan dermatologic diseases.
The Company’s investigational therapies have proven mechanisms-of-action backed
by decades of clinical experience and well-established CMC (chemistry,
manufacturing and control) and safety profiles. The Company is initially
focused on developing non-systemic treatments for rare dermatologic diseases
including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and localized scleroderma. For more information,
visit www.timberpharma.com.
About LD
Micro/SEQUIRE
LD Micro
began in 2006 with the sole purpose of being an independent resource to the
microcap world. What started as a newsletter highlighting unique companies, has
transformed into the pre-eminent event platform in the space. For more
information, please visit ldmicro.com.
The
upcoming Main Event will be highlighting a new format that will benefit both
executives and the investors tuning in from all over the globe.
In
September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial
technology company that unlocks data and insights for publicly traded
companies. Through its premier investor intelligence and communications
platform, Sequire, companies can track their investors’
behaviors and trends and use those insights to engage current and potential investors
across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.
Forward-Looking
Statements
This press
release contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended,
including those relating to the Company’s product development, clinical and
regulatory timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies, potential growth
opportunities and other statements that are predictive in nature. These
forward-looking statements are based on current expectations, estimates,
forecasts and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions.
These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,”
“intend,” “plan,” “believe,”
“estimate,” “potential, “predict,”
“project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s Form 10-Q filed on August 18,
2020 and its other filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this press
release. The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
For more
information, contact:
Timber
Pharmaceuticals, Inc.
John
Koconis
Chief
Executive Officer
jkoconis@timberpharma.com
Investor
Relations:
Stephanie
Prince
PCG
Advisory
(646)
762-4518
sprince@pcgadvisory.com
Media
Relations:
Adam Daley
Berry &
Company Public Relations
(212)
253-8881
adaley@berrypr.com
Source: Timber
Pharmaceuticals via LD Micro
[ad_2]